Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 10/20 | 1.00 |
| ▸ | CPB1 | P15086 | 1/20 | 0.66 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | MMP2 | P08253 | 1/20 | 0.60 |
| ▸ | MMP9 | P14780 | 1/20 | 0.60 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.59 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18145488 | 1.00 | FOLH1 (1.00) | FOLH1CPB1CPB2HTTMMP2 | |
| SCHEMBL18161459 | 1.00 | FOLH1 (1.00) | FOLH1CPB1CPB2HTTMMP2 | |
| SCHEMBL14729484 | 1.00 | FOLH1 (1.00) | FOLH1CPB1CPB2HTTMMP2 | |
| SCHEMBL19743113 | 0.97 | FOLH1 (0.93) | FOLH1CPB1CPB2HTTMMP2 | |
| SCHEMBL19743114 | 0.97 | FOLH1 (0.93) | FOLH1CPB1CPB2HTTMMP2 | |
| SCHEMBL19743085 | 0.96 | FOLH1 (0.92) | FOLH1CPB1CPB2HTTMMP2 | |
| SCHEMBL19743088 | 0.96 | FOLH1 (0.92) | FOLH1CPB1CPB2HTTMMP2 | |
| SCHEMBL18145837 | 0.91 | FOLH1 (1.00) | FOLH1CPB1CPB2HTTMMP2 | |
| SCHEMBL18161580 | 0.91 | FOLH1 (1.00) | FOLH1CPB1CPB2HTTMMP2 | |
| SCHEMBL22712984 | 0.91 | FOLH1 (1.00) | FOLH1CPB1CPB2HTTMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076128-A1 | ADAPTORS FOR ADOPTIVE CELL THERAPY AND COMPOUNDS FOR PREPARING SAME | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20240425547-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2024-12-26 | — | — | US | disclosed |
| US-12122851-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2024-10-22 | — | — | US | disclosed |
| WO-2024116053-A1 | PCTA DERIVATIVES, CONJUGATES THEREOF AND USES THEREOF | NOVARTIS AG (CH) | 2024-06-06 | — | — | WO | disclosed |
| EP-4249005-A2 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | Cornell University (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3493856-B1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | UNIV CORNELL (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | RIGSHOSPITALET (DK) | 2023-06-29 | — | — | US | disclosed |
| WO-2023097038-A1 | CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | FULL-LIFE TECHNOLOGIES U.S. INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-4161585-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | University of Copenhagen (DK) | 2023-04-12 | — | — | EP | disclosed |
| US-20220194904-A1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | CORNELL UNIVERSITY (US) | 2022-06-23 | — | — | US | disclosed |
| US-10894807-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20200377549-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200377549-A1 | PSMA Imaging Agents | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200317588-A1 | 18F-LABELED PEPTIDE LIGANDS USEFUL IN PET AND CERENKOV LUMINESCENE IMAGING | CORNELL UNIVERSITY (US) | 2020-10-08 | — | — | US | disclosed |
| US-10716772-B2 | Double targeted constructs to affect tumor kill | CORNELL UNIVERSITY (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190142770-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | CORNELL UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| US-10179117-B2 | Double targeted constructs to affect tumor kill | CORNELL UNIVERSITY (US) | 2019-01-15 | — | — | US | disclosed |
| US-10011632-B2 | PSMA imaging agents | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170369454-A1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | UNIV CORNELL (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170368005-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | CORNELL UNIVERSITY | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425547-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | FOLH1 1/4885CPB1 293/4885CPB2 566/4885 |
| US-10894807-B2 | PSMA imaging agents | FOLH1, KLK3, PSMA2 | FOLH1 1/4885CPB1 293/4885CPB2 566/4885 |
| US-20200317588-A1 | 18F-LABELED PEPTIDE LIGANDS USEFUL IN PET AND CERENKOV LUMINESCENE IMAGING | VIP, CALCA, GLP1R | FOLH1 33/4885CPB1 695/4885CPB2 1293/4885 |
| US-20230201383-A1 | PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING | KLK3, FOLH1, PSMA7 | FOLH1 2/4885CPB1 658/4885CPB2 776/4885 |
| US-10716772-B2 | Double targeted constructs to affect tumor kill | PSMA2, FOLH1, KLK3 | FOLH1 2/4885CPB1 396/4885CPB2 130/4885 |
| US-20170368005-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | PSMA2, FOLH1, KLK3 | FOLH1 2/4885CPB1 396/4885CPB2 130/4885 |
| US-20190142770-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | PSMA2, FOLH1, KLK3 | FOLH1 2/4885CPB1 396/4885CPB2 130/4885 |
| US-10179117-B2 | Double targeted constructs to affect tumor kill | PSMA2, FOLH1, KLK3 | FOLH1 2/4885CPB1 396/4885CPB2 130/4885 |
| US-20170369454-A1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | PSMA3, FOLH1, PSMA1 | FOLH1 2/4885CPB1 986/4885CPB2 1829/4885 |
| US-20200377549-A1 | PSMA Imaging Agents | FOLH1, KLK3, PSMA2 | FOLH1 1/4885CPB1 293/4885CPB2 566/4885 |
| US-10011632-B2 | PSMA imaging agents | FOLH1, KLK3, PSMA2 | FOLH1 1/4885CPB1 293/4885CPB2 566/4885 |
| US-12122851-B2 | PSMA imaging agents | FOLH1, KLK3, PSMA2 | FOLH1 1/4885CPB1 293/4885CPB2 566/4885 |
| US-20220194904-A1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | PSMA3, FOLH1, PSMA1 | FOLH1 2/4885CPB1 986/4885CPB2 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.